Regulus Therapeutics (Regulus Therapeutics) Short Interest

View and export this data going back to 2012. Start your Free Trial

What is Regulus Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Regulus Therapeutics's Short Interest

For the Biotechnology subindustry, Regulus Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regulus Therapeutics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regulus Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Regulus Therapeutics's Short Interest falls into.

Regulus Therapeutics (Regulus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (NAS:RGLS) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

7RG0:Germany

Address

4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121

Website

https://www.regulusrx.com

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.

Executives

Crispina Calsada	officer: Chief Financial Officer	C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Christopher Ray Aker	officer: Sr. VP & General Counsel	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Joseph P Hagan	officer: Chief Operating Officer	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Preston Klassen	officer: President & Head of R & D	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Denis Drygin	officer: Chief Scientific Officer	10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Alice Shih-hou Huang	director	10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Ali Behbahani	10 percent owner	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Forest Baskett	10 percent owner
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Paul Edward Walker	director	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott D Sandell	10 percent owner